4.6 Article

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

期刊

BMJ OPEN
卷 4, 期 6, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2014-005559

关键词

-

资金

  1. JDRF [9-2011-253]
  2. Wellcome Trust [091157, 100140]
  3. National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
  4. European Union [241447]
  5. MRC [MC_UP_1302/2] Funding Source: UKRI
  6. Medical Research Council [MC_UP_1302/2] Funding Source: researchfish
  7. National Institute for Health Research [NF-SI-0513-10143, NF-SI-0508-10275] Funding Source: researchfish

向作者/读者索取更多资源

Introduction: CD4 T regulatory cells (Tregs) are crucial for the maintenance of self-tolerance and are deficient in many common autoimmune diseases such as type 1 diabetes (T1D). Interleukin 2 (IL-2) plays a major role in the activation and function of Tregs and treatment with ultra-low dose (ULD) IL-2 could increase Treg function to potentially halt disease progression in T1D. However, prior to embarking on large phase II/III clinical trials it is critical to develop new strategies for determining the mechanism of action of ULD IL-2 in participants with T1D. In this mechanistic study we will combine a novel trial design with a clinical grade Treg assay to identify the best doses of ULD IL-2 to induce targeted increases in Tregs. Method and analysis: Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D) is a single centre non-randomised, single dose, open label, adaptive dose-finding trial. The primary objective of DILT1D is to identify the best doses of IL-2 to achieve a minimal or maximal Treg increase in participants with T1D (N=40). The design has an initial learning phase where pairs of participants are assigned to five preassigned doses followed by an interim analysis to determine the two Treg targets for the reminder of the trial. This will then be followed by an adaptive phase which is fully sequential with an interim analysis after each participant is observed to determine the choice of dose based on the optimality criterion to minimise the determinant of covariance of the estimated target doses. A dose determining committee will review all data available at the interim(s) and then provide decisions regarding the choice of dose to administer to subsequent participants. Ethics and dissemination: Ethical approval for the study was granted on 18 February 2013. Results: The results of this study will be reported through peer-reviewed journals, conference presentations and an internal organisational report.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据